

Sergei M Danilov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5698628/publications.pdf>

Version: 2024-02-01

63
papers

2,573
citations

159525

30
h-index

197736

49
g-index

64
all docs

64
docs citations

64
times ranked

1747
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. <i>Nature Biotechnology</i> , 2001, 19, 838-842.	9.4	219
2	A Targetable, Injectable Adenoviral Vector for Selective Gene Delivery to Pulmonary Endothelium in Vivo. <i>Molecular Therapy</i> , 2000, 2, 562-578.	3.7	203
3	Cellular Distribution of Angiotensin-Converting Enzyme After Myocardial Infarction. <i>Hypertension</i> , 1995, 25, 219-226.	1.3	132
4	Unique Toll-Like Receptor 4 Activation by NAMPT/PBEF Induces NF κ B Signaling and Inflammatory Lung Injury. <i>Scientific Reports</i> , 2015, 5, 13135.	1.6	126
5	Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 280, L1335-L1347.	1.3	116
6	Angiotensin-converting enzyme in non-neoplastic kidney diseases. <i>Kidney International</i> , 1999, 56, 1442-1454.	2.6	87
7	Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. <i>Experimental Hematology</i> , 2003, 31, 1301-1309.	0.2	81
8	ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition?. , 2007, 113, 607-618.		78
9	Development of enzyme-linked immunoassays for human angiotensin I converting enzyme suitable for large-scale studies. <i>Journal of Hypertension</i> , 1996, 14, 719-727.	0.3	70
10	Heterogeneous distribution of angiotensin I-converting enzyme (CD143) in the human and rat vascular systems: Vessel, organ and species specificity. <i>Microvascular Research</i> , 2011, 81, 206-215.	1.1	59
11	Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats. <i>Molecular Therapy</i> , 2005, 12, 321-327.	3.7	58
12	Propofol Attenuates Lung Endothelial Injury Induced by Ischemia-Reperfusion and Oxidative Stress. <i>Anesthesia and Analgesia</i> , 2005, 100, 929-936.	1.1	58
13	Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1998, 275, L806-L817.	1.3	56
14	Point Mutation in the Stalk of Angiotensin-Converting Enzyme Causes a Dramatic Increase in Serum Angiotensin-Converting Enzyme But No Cardiovascular Disease. <i>Circulation</i> , 2001, 104, 1236-1240.	1.6	51
15	Immunotargeting of catalase to lung endothelium via anti-angiotensin-converting enzyme antibodies attenuates ischemia-reperfusion injury of the lung in vivo. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007, 293, L162-L169.	1.3	48
16	Gene Therapy by Targeted Adenovirus-mediated Knockdown of Pulmonary Endothelial Tph1 Attenuates Hypoxia-induced Pulmonary Hypertension. <i>Molecular Therapy</i> , 2012, 20, 1516-1528.	3.7	48
17	Inhibitory Antibodies to Human Angiotensin-Converting Enzyme: Fine Epitope Mapping and Mechanism of Action. <i>Biochemistry</i> , 2006, 45, 4831-4847.	1.2	45
18	Interaction of mAb to angiotensin-converting enzyme (ACE) with antigen in vitro and in vivo: antibody targeting to the lung induces ACE antigenic modulation. <i>International Immunology</i> , 1994, 6, 1153-1160.	1.8	40

#	ARTICLE	IF	CITATIONS
19	Epitope-specific antibody-induced cleavage of angiotensin-converting enzyme from the cell surface. <i>Biochemical Journal</i> , 2002, 362, 585-595.	1.7	40
20	Epitope-Dependent Blocking of the Angiotensin-Converting Enzyme Dimerization by Monoclonal Antibodies to the N-Terminal Domain of ACE: A Possible Link of ACE Dimerization and Shedding from the Cell Surface. <i>Biochemistry</i> , 2003, 42, 6965-6976.	1.2	39
21	Modulation of angiotensin-converting enzyme in cultured human vascular endothelial cells. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 1998, 34, 545-554.	0.7	38
22	An Angiotensin I-Converting Enzyme Mutation (Y465D) Causes a Dramatic Increase in Blood ACE via Accelerated ACE Shedding. <i>PLoS ONE</i> , 2011, 6, e25952.	1.1	37
23	Fine epitope mapping of monoclonal antibodies 9B9 and 3G8 to the N domain of angiotensin-converting enzyme (CD143) defines a region involved in regulating angiotensin-converting enzyme dimerization and shedding. <i>Tissue Antigens</i> , 2010, 75, 136-150.	1.0	36
24	Conformational Fingerprinting of the Angiotensin I-Converting Enzyme (ACE). 1. Application in Sarcoidosis. <i>Journal of Proteome Research</i> , 2010, 9, 5782-5793.	1.8	34
25	Monoclonal antibodies to native mouse angiotensin-converting enzyme (CD143): ACE expression quantification, lung endothelial cell targeting and gene delivery. <i>Tissue Antigens</i> , 2006, 67, 10-29.	1.0	32
26	Monoclonal Antibodies 1G12 and 6A12 to the N-Domain of Human Angiotensin-Converting Enzyme: A Fine Epitope Mapping and Antibody-Based Detection of ACE Inhibitors in Human Blood. <i>Journal of Proteome Research</i> , 2007, 6, 1580-1594.	1.8	32
27	Simultaneous Determination of ACE Activity with 2 Substrates Provides Information on the Status of Somatic ACE and Allows Detection of Inhibitors in Human Blood. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 52, 90-103.	0.8	32
28	Testicular Isoform of Angiotensin I-Converting Enzyme (ACE, CD143) on the Surface of Human Spermatozoa: Revelation and Quantification Using Monoclonal Antibodies. <i>American Journal of Reproductive Immunology</i> , 2006, 55, 54-68.	1.2	31
29	Angiotensin I-Converting Enzyme Mutation (Trp1197Stop) Causes a Dramatic Increase in Blood ACE. <i>PLoS ONE</i> , 2009, 4, e8282.	1.1	31
30	Limited Proteolysis of Human Kidney Angiotensin-Converting Enzyme and Generation of Catalytically Active N- and C-Terminal Domains. <i>Biochemical and Biophysical Research Communications</i> , 1997, 236, 16-19.	1.0	30
31	Somatic isoform of angiotensin converting enzyme in the pathology of testicular germ cell tumors. <i>Human Pathology</i> , 2000, 31, 1466-1476.	1.1	30
32	Localization of an N-Domain Region of Angiotensin-Converting Enzyme Involved in the Regulation of Ectodomain Shedding Using Monoclonal Antibodies. <i>Journal of Proteome Research</i> , 2005, 4, 258-267.	1.8	30
33	Epitope-specific antibody-induced cleavage of angiotensin-converting enzyme from the cell surface. <i>Biochemical Journal</i> , 2002, 362, 585.	1.7	28
34	ACE phenotyping in Gaucher disease. <i>Molecular Genetics and Metabolism</i> , 2018, 123, 501-510.	0.5	28
35	Lysozyme and bilirubin bind to ACE and regulate its conformation and shedding. <i>Scientific Reports</i> , 2016, 6, 34913.	1.6	27
36	Selective rat lung endothelial targeting with a new set of monoclonal antibodies to angiotensin I-converting enzyme. <i>Pulmonary Pharmacology and Therapeutics</i> , 2005, 18, 251-267.	1.1	26

#	ARTICLE	IF	CITATIONS
37	Mapping of Conformational mAb Epitopes to the C Domain of Human Angiotensin I-Converting Enzyme. <i>Journal of Proteome Research</i> , 2008, 7, 3396-3411.	1.8	26
38	Angiotensin I-Converting Enzyme Gln1069Arg Mutation Impairs Trafficking to the Cell Surface Resulting in Selective Denaturation of the C-Domain. <i>PLoS ONE</i> , 2010, 5, e10438.	1.1	26
39	Monoclonal Antibodies 1B3 and 5C8 as Probes for Monitoring the Integrity of the C-Terminal End of Soluble Angiotensin-Converting Enzyme. <i>Hybridoma</i> , 2005, 24, 14-26.	0.5	25
40	Fine Epitope Mapping of Monoclonal Antibody 5F1 Reveals Anticatalytic Activity toward the N Domain of Human Angiotensin-Converting Enzyme. <i>Biochemistry</i> , 2007, 46, 9019-9031.	1.2	24
41	Detection of Mutated Angiotensin I-Converting Enzyme by Serum/Plasma Analysis Using a Pair of Monoclonal Antibodies. <i>Clinical Chemistry</i> , 2005, 51, 1040-1043.	1.5	23
42	Pre-ischaemic conditioning of the pulmonary endothelium by immunotargeting of catalase via angiotensin-converting-enzyme antibodies. <i>European Journal of Cardio-thoracic Surgery</i> , 2010, 37, 859-863.	0.6	23
43	Tissue Specificity of Human Angiotensin I-Converting Enzyme. <i>PLoS ONE</i> , 2015, 10, e0143455.	1.1	22
44	A Novel Splice-Site Mutation in Angiotensin I-Converting Enzyme (ACE) Gene, c.3691+1G>A (IVS25+1G>A), Causes a Dramatic Increase in Circulating ACE through Deletion of the Transmembrane Anchor. <i>PLoS ONE</i> , 2013, 8, e59537.	1.1	22
45	Angiotensin I-converting enzyme and potential substrates in human testis and testicular tumours. Review article. <i>Apmis</i> , 2003, 111, 234-244.	0.9	21
46	A Novel Angiotensin I-Converting Enzyme Mutation (S333W) Impairs N-Domain Enzymatic Cleavage of the Anti-Fibrotic Peptide, AcSDKP. <i>PLoS ONE</i> , 2014, 9, e88001.	1.1	19
47	A study of chimeras constructed with the two domains of angiotensin I-converting enzyme. <i>Biochemical Pharmacology</i> , 1996, 51, 11-14.	2.0	18
48	ACE phenotyping in human heart. <i>PLoS ONE</i> , 2017, 12, e0181976.	1.1	18
49	Epitope mapping of mAbs to denatured human testicular ACE (CD143). <i>Tissue Antigens</i> , 2008, 72, 354-368.	1.0	17
50	Development and characterization of rat monoclonal antibodies to denatured mouse angiotensin-converting enzyme. <i>Tissue Antigens</i> , 2005, 65, 240-251.	1.0	16
51	Tissue ACE phenotyping in lung cancer. <i>PLoS ONE</i> , 2019, 14, e0226553.	1.1	16
52	Conformational Changes of Blood ACE in Chronic Uremia. <i>PLoS ONE</i> , 2012, 7, e49290.	1.1	15
53	ACE Phenotyping as a Guide Toward Personalized Therapy With ACE Inhibitors. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017, 22, 374-386.	1.0	14
54	Peptidyl-Dipeptidase A/Angiotensin I-Converting Enzyme. , 2013, , 480-494.		13

#	ARTICLE	IF	CITATIONS
55	Novel ACE mutations mimicking sarcoidosis by increasing blood ACE levels. <i>Translational Research</i> , 2021, 230, 5-20.	2.2	12
56	Conformational fingerprint of blood and tissue ACEs: Personalized approach. <i>PLoS ONE</i> , 2018, 13, e0209861.	1.1	8
57	Hereditary hyper-ACE-emia due to the Pro1199Leu mutation of somatic ACE as a potential pitfall in diagnosis: a first family outside Europe. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 1088-9.	1.4	7
58	Conformational "Fingerprint" of the Angiotensin-Converting Enzyme. <i>Russian Journal of Bioorganic Chemistry</i> , 2018, 44, 52-63.	0.3	7
59	Epitope mapping of novel monoclonal antibodies to human angiotensin converting enzyme. <i>Protein Science</i> , 2021, 30, 1577-1593.	3.1	7
60	Phenotyping Angiotensin-Converting Enzyme in Blood: A Necessary Approach for Precision Medicine. <i>Journal of Applied Laboratory Medicine</i> , 2021, 6, 1179-1191.	0.6	7
61	Tissue ACE phenotyping in prostate cancer. <i>Oncotarget</i> , 2019, 10, 6349-6361.	0.8	7
62	Reduced expression of angiotensin I-converting enzyme in Caveolin-1 knockout mouse lungs. <i>Microvascular Research</i> , 2010, 80, 250-257.	1.1	4
63	Intravascular Re-Targeting of Viral Vectors. , 2002, , 173-190.		0